formally known as gpha

Same medicine. Same results.
Lower cost.

GPhA Announces 2016 Board of Directors

Contact: Steve Arnoff 202.249.7113

 

ORLANDO, FL (February 22, 2016) — The Generic Pharmaceutical Association (GPhA) today at its 2016 Annual Meeting announced the election of its 2016 Board of Directors and Executive Committee.

Mylan CEO Heather Bresch is the 2016 GPhA Chair of the Board. GPhA also named Jeff Watson, President, Global Generics, Apotex, Inc. as Vice-Chairman of the Board and Tony Pera, Chief Commercial Officer, Par Pharmaceuticals, as Secretary-Treasurer.

“I’m very excited to lead GPhA as chair once again and advocate on behalf of the generic pharmaceutical industry to continue our remarkable record of delivering significant savings to patients and the overall healthcare system,” said Bresch. “Now more than ever it is critical that GPhA is the leading voice for safe, effective and more affordable medicines, and that the indisputable value of generics and biosimilars is made crystal clear for policymakers, regulators and stakeholders in today’s dynamic healthcare market.”

Generic drugs saved the U.S. health system $254 billion in 2014, according to the Generic Drug Savings in the U.S. report compiled by the IMS Institute for Health on behalf of GPhA.

“Generic drugs drive savings, not costs,” said Chip Davis, GPhA President and CEO. “Our newly elected Board is an exceptionally strong leadership team with bold vision for the future and a firm grasp on the challenges and opportunities facing this industry. I look forward to guiding GPhA collaboration with FDA to reduce the backlog of generic applications, working with Congress and others to enact policies that enhance patient and health system savings, and assuring Americans have timely access to vital generic drugs and biosimilars.”

“This industry continues to be the most reliable source of savings in the health sector,” said Watson. “I look forward to working with the association leadership to advance the mission of GPhA and its member companies, improving the lives of millions of patients while enhancing timely access to quality, affordable medicines.”

“GPhA is well positioned to increase our share of voice with legislators, regulators and other key constituencies, and I am excited to be a part of our industry efforts,” said Pera.”

The 2016 GPhA Board of Directors includes:

* Debra Barrett (Teva Americas)

* Heather Bresch (Mylan N.V.)*

* Robert Cunard (Aurobindo Pharma US)

* John Ducker (Fresenius-Kabi)

* Peter Goldschmidt (Sandoz US)

* Jim Kedrowski (Sun Pharmaceuticals)

* Marcy Macdonald (Impax Laboratories)

* Paul McGarty (Lupin Pharmaceuticals)

* Chirag Patel (Amneal Pharmaceuticals)

* Tony Pera (Par Pharmaceuticals)

* Joseph Renner (Zydus Pharmaceuticals, Inc.)

* Richard Stec (Perrigo Company)

* Alok Sonig (Dr. Reddy’s Laboratories)

* Jeff Watson (Apotex Corporation)

* Craig Wheeler (Momenta Pharmaceuticals)

 

About GPhA

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.